R3tatrutide: sourcing and COA guide
R3tatrutide is an investigational triple agonist targeting the GLP-1, GIP, and glucagon (GCGR) receptors. For laboratories evaluating emerging incretin-class reference compounds, the sourcing bar is high: identity, purity, and batch-level Certificates of Analysis must be verified before any research use.
Mechanism at a glance
R3tatrutide is a synthetic peptide engineered as a balanced agonist at three incretin and glucagon-family receptors:
- GLP-1R — glucose-dependent insulinotropic activity.
- GIPR — potentiates insulin release and modulates adipocyte signaling.
- GCGR — glucagon receptor engagement associated with energy expenditure.
The triple-agonist profile is what distinguishes it from single-target GLP-1 references and dual GLP-1 / GIP agonists.
Purity and identity standards
Mass and purity
A laboratory may report measured mass and a purity result for the submitted sample. Purity results are reported by batch in the applicable Quality Report.
Identity
Identity testing is intended to confirm that the submitted sample corresponds to the named compound, using the method the laboratory identifies on the report.
Every batch is independently tested for mass and purity, identity, and endotoxins. Every unit shipped is traceable to a specific batch and its independent Quality Report.
What a good COA includes
- Compound name
- Batch or lot number
- Testing laboratory
- Test or report date
- Identity result
- Mass and purity result
- Endotoxin result
- The analytical method identified by the laboratory
For a field-by-field walkthrough, see How to Understand a Certificate of Analysis, or browse the Quality Reports archive.
For research use only
R3tatrutide is supplied strictly for in-vitro laboratory research. It is not a drug, is not for human or veterinary use, and is not intended to diagnose, treat, cure, or prevent any disease.